Italfarmaco Spa Drug Patent Portfolio
Italfarmaco Spa owns 1 orange book drug protected by 4 US patents Given below is the list of Italfarmaco Spa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10688047 | Physically and chemically stable oral suspensions of givinostat | 28 Oct, 2036 | Active |
| US9421184 | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy | 03 Feb, 2032 | Active |
| US9867799 | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy | 03 Feb, 2032 | Active |
| US7329689 | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester | 15 Jan, 2025 | Active |
Latest Legal Activities on Italfarmaco Spa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Italfarmaco Spa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US9867799 |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US10688047 |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US9421184 |
| Patent Term Extension Application under 35 USC 156 Filed | 17 May, 2024 | US7329689 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 15 May, 2024 | US9867799 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 15 May, 2024 | US9421184 |
|
Email Notification
Critical
| 15 May, 2024 | US9867799 |
|
Email Notification
Critical
| 15 May, 2024 | US9421184 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 23 Feb, 2024 | US9421184 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 26 Dec, 2023 | US10688047 |
|
Interim Patent Term Extension Granted
Critical
| 21 Nov, 2023 | US7329689 |
|
Email Notification
Critical
| 03 Aug, 2023 | US7329689 |
|
Electronic Review
Critical
| 02 Aug, 2023 | US7329689 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 31 Jul, 2023 | US7329689 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 16 Jul, 2021 | US9867799 |
Italfarmaco Spa's Family Patents
Italfarmaco Spa Drug List
Given below is the complete list of Italfarmaco Spa's drugs and the patents protecting them.
1. Duvyzat
Duvyzat is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10688047 | Physically and chemically stable oral suspensions of givinostat |
28 Oct, 2036
(11 years from now)
| Active |
| US9421184 | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
03 Feb, 2032
(7 years from now)
| Active |
| US9867799 | Diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride for use in the treatment of muscular dystrophy |
03 Feb, 2032
(7 years from now)
| Active |
| US7329689 | Monohydrate hydrochloride of the 4-hydroxycarbamoyl-phenyl)-carbamic acid (6-diethylaminomethyl-naphtalen-2-yl) ester |
15 Jan, 2025
(a month from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Duvyzat's drug page